- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01694069
Continuous Infusion Piperacillin-tazobactam for the Treatment of Cystic Fibrosis (PIPE-CF)
Continuous Infusion Piperacillin-Tazobactam for the Treatment of Pulmonary Exacerbations in Patients With Cystic Fibrosis
Cystic fibrosis is an inherited disorder leading to chronic pulmonary inflammation and infection. A majority of people with cystic fibrosis have large quantities of bacteria residing in their lungs. One of the most common and harmful bacteria is called Pseudomonas aeruginosa.
Patients with cystic fibrosis require frequent therapy with intravenous (I.V.) antibiotics to treat lung infections thought to be caused by Pseudomonas aeruginosa. One of the antibiotics frequently used to treat this bacteria is piperacillin-tazobactam. Piperacillin-tazobactam is thought to be the most effective when there is a constant level of drug in the body. The standard way to administer piperacillin-tazobactam is to give several grams 4 times each day as a 30 minute infusion. An alternative way to give piperacillin-tazobactam is by a continuous infusion; a continuous infusion will make it more likely that drug will remain at a constant level in the body. The objective of this study is to determine if administering piperacillin-tazobactam as a continuous infusion is more effective at treating people having a pulmonary exacerbation of cystic fibrosis than a standard 30 minute infusion, 4 times a day.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
All patients will receive combination therapy to include piperacillin-tazobactam 400 mg/kg/day (based on piperacillin component, actual body weight) not to exceed 16 grams and tobramycin 12 mg/kg/day extended interval dosing (once daily). Patients randomized to the continuous infusion group will receive a one-time loading dose of 100 mg/kg over 30 minutes followed immediately by initiation of the continuous infusion.
Other antibiotics with activity against Pseudomonas aeruginosa are not allowed. Patients may receive an antibiotic for treatment of Staphylococcus aureus if deemed appropriate.
Other treatments for pulmonary exacerbation of cystic fibrosis will be left up to the control of the treating physician. Patients will receive a total of 14 days of therapy. If deemed appropriate, patients may be discharged to home where they will continue to receive blinded treatment via an infusion pump. Patients will be evaluated after completing their 14 day course of antibiotics (end of therapy).
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
West Virginia
-
Morgantown, West Virginia, United States, 26505
- West Virginia University Healthcare
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of cystic fibrosis
- 8 years of age or greater
- Chronic or intermittent infection with Pseudomonas aeruginosa as defined by the Leeds Criteria
- Pulmonary exacerbation as defined by Fuchs et al.
Exclusion Criteria:
- Admission for greater than 48 hours prior to enrollment
- Isolation of Burkholderia spp. in a respiratory tract culture in the prior 12 months
- Current treatment for allergic bronchopulmonary aspergillosis
- Pregnant or breast feeding
- History of solid organ transplantation
- Renal impairment at time of randomization (< 40 mL/min as calculated by the Cockcroft-Gault equation24 ¬for adults or the Schwartz equation45 for those < 18 years of age) or receipt of hemodialysis
- Allergy to study medication
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Intermittent Infusion piperacillin-tazobactam
Piperacillin-tazobactam administered at a dose of 400 mg/kg/day (maximum of 16 grams), divided in four equal doses, administered over 30 minutes, four times a day
|
400 mg/kg/day as either intermittent or continuous infusion
Other Names:
|
Experimental: Continuous infusion piperacillin-tazobactam
Piperacillin-tazobactam administered at a dose of 400 mg/kg/day (maximum of 16 grams) as a continuous infusion over 24 hours, once daily
|
400 mg/kg/day as either intermittent or continuous infusion
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Forced Expiratory Volume at One Second (FEV1)
Time Frame: Baseline, Day 0, and Day 14
|
FEV1 will be measured upon enrollment (day 0).
FEV1 will also be measured at end of therapy (day 14).
If FEV1 is available when patient was stable, prior to enrollment, this value will be treated as baseline FEV1.
Change in FEV1 will be calculated from baseline (if available) to day 14 and also Day 0 to day 14
|
Baseline, Day 0, and Day 14
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Piperacillin Serum Concentrations
Time Frame: Day 3
|
Serum piperacillin concentration will be measured as follows:
|
Day 3
|
Time to Next Pulmonary Exacerbation
Time Frame: Patients will be followed up to 52 weeks from time of enrollment
|
Patients will be followed for time of next subsequent pulmonary exacerbation for up to 52 weeks after completion of receiving study drug.
Next pulmonary exacerbation is defined as requiring admission to a hospital for receipt of I.V. antibiotics because of a diagnosis of pulmonary exacerbation.
|
Patients will be followed up to 52 weeks from time of enrollment
|
Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Score
Time Frame: Day 0 and day 14
|
The validated CFQ-R will be administered to patients at time of enrollment at end of therapy
|
Day 0 and day 14
|
Change in Sputum Density of Pseudomonas Aeruginosa
Time Frame: Day 0, day 3, and day 14
|
Sputum density of Pseudomonas aeruginosa will be determined at enrollment, day 3, and at end of therapy
|
Day 0, day 3, and day 14
|
Change in Weight
Time Frame: Day 0 and day 14
|
The change in weight will be documented from enrollment to end of therapy
|
Day 0 and day 14
|
Time to Defervescence
Time Frame: Day 0 to day 14
|
Temperature will be taken multiple times daily according to standard of care.
If patients present febrile, time until patient is afebrile and remains afebrile for 24 hours will be recorded.
|
Day 0 to day 14
|
Time to Normalization of White Blood Cell Count
Time Frame: Day to day 14
|
White blood cell (WBC) count will be measured once daily.
If patient presents with WBC count greater than 11.0 x 10^3/mL, time until patient has WBC less than 11.0 x 10^3/mL will be recorded.
|
Day to day 14
|
Clinical Failure of Treatment
Time Frame: Day 14
|
Failure of treatment will be defined as patient needing I.V. antibiotics beyond the 14 days allowed in this study.
The primary medical team (along with a blinded investigator) treating the patient will determine whether patient requires additional therapy.
|
Day 14
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Lisa Biondo, PharmD, West Virginia University Healthcare
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Respiratory Tract Diseases
- Lung Diseases
- Infant, Newborn, Diseases
- Genetic Diseases, Inborn
- Pancreatic Diseases
- Fibrosis
- Cystic Fibrosis
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Anti-Bacterial Agents
- beta-Lactamase Inhibitors
- Piperacillin
- Tazobactam
- Piperacillin, Tazobactam Drug Combination
Other Study ID Numbers
- 24255
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cystic Fibrosis
-
Hospital de Clinicas de Porto AlegreUnknownCystic Fibrosis | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in Children | Cystic Fibrosis With ExacerbationBrazil
-
University of Colorado, DenverCystic Fibrosis FoundationTerminatedCystic Fibrosis-related Diabetes | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in ChildrenUnited States
-
Royal College of Surgeons, IrelandThe Hospital for Sick Children; Imperial College London; Erasmus Medical Center; University College Dublin and other collaboratorsActive, not recruitingCystic Fibrosis | Adherence, Medication | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in Children | Cystic Fibrosis Liver DiseaseUnited Kingdom, Ireland
-
Herlev and Gentofte HospitalCopenhagen University Hospital, DenmarkActive, not recruitingMyocardial Infarction | Heart Diseases | Heart Failure | Stroke | Cystic Fibrosis | Heart Failure, Diastolic | Heart Failure, Systolic | Left Ventricular Dysfunction | Cystic Fibrosis-related Diabetes | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis of Pancreas | Cystic Fibrosis, Pulmonary | Cystic...Denmark
-
The Hospital for Sick ChildrenCanadian Cystic Fibrosis FoundationActive, not recruitingCystic Fibrosis | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in ChildrenCanada
-
AzurRx SASCompletedCystic Fibrosis | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis of PancreasTurkey, Hungary
-
Arrowhead PharmaceuticalsTerminatedCystic Fibrosis, PulmonaryAustralia, New Zealand
-
Dartmouth-Hitchcock Medical CenterTrustees of Dartmouth CollegeWithdrawnCystic Fibrosis-related Diabetes | Cystic Fibrosis Liver Disease | CF - Cystic FibrosisUnited States
-
University of PortsmouthUniversity Hospital Southampton NHS Foundation Trust; Loughborough University; Queen Alexandra HospitalTerminated
-
University Hospital, BordeauxCompleted
Clinical Trials on Piperacillin-tazobactam combination product
-
St. Justine's HospitalUnknown
-
Karolinska InstitutetCompletedCholecystitis, AcuteSweden
-
Chinese PLA General HospitalUnknownNeutropenia | Hematopoietic Stem Cell TransplantationChina
-
Nabriva Therapeutics AGMedpace, Inc.CompletedAcute Pyelonephritis | Urinary Tract Infection Complicated | Urinary Tract Infection SymptomaticPoland, Ukraine, Belarus, Bulgaria, Romania, Greece, United States, Russian Federation, Hungary, Lithuania, Slovakia, Czechia, Latvia, Croatia, Georgia, Estonia
-
Chinese PLA General HospitalCompletedNeutropenia | Hematopoietic Stem Cell Transplantation | FebrileChina
-
The University of QueenslandCompletedBloodstream InfectionsSingapore, Australia
-
University GhentKing Baudouin Foundation; Belgische Vereniging voor Strijd tegen MucoviscidoseTerminated
-
The University of QueenslandAustralasian Society for Infectious Diseases; International Society of Chemotherapy and other collaboratorsTerminatedBloodstream InfectionsAustralia, Singapore, South Africa, Italy, Saudi Arabia, Canada, Lebanon, New Zealand, Turkey
-
Gruppo Italiano per la Valutazione degli Interventi...Completed
-
Fundación Pública Andaluza para la gestión de la...Hospital Son Espases; Hospital Universitario Virgen Macarena; Hospital Son Llatzer and other collaboratorsCompletedPseudomonas Aeruginosa InfectionSpain